Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study

Lancet

Volumn 354, Issue 9172, 1999, Pages 13-19

  Chadwick, David ^a   Baldy Moulinier, J ^b   Ben Manachem, E ^b   Beran, R ^b   Bes, A ^b   Biermann, L D ^b   Bird, J M ^b   Boon, L ^b   Byrne, E ^b   Calandre, E P ^b   de Seijas, E V ^b   Tejerina, J A ^b   Canger, R ^b   Saltarelli, A ^b   Cartlidge, N E F ^b   Corston, R N ^b   Cosi, V ^b   Dellaportas, C ^b   Duncan, J ^b   Van Paesschen, W ^b   Dam, M ^b   Danta, G ^b   Gadot, H ^b   Gale, A N ^b   Gisselbrecht, D ^b   Gross, M ^b   Guldenpfennig, W M ^b   Haan, J ^b   Howell, S J L ^b   Venables, G S ^b   Jankovic, J ^b   Kalviainen R ^b   Riekkinen, P ^b   Kennedy, K ^b   Kramer, G ^b   Kritzinger, P H ^b   Manelis, J ^b   Michelucci, R ^b   Tassinari, C A ^b   Neufeld, M ^b   Pederson, B ^b   Pisani, F ^b   Reches, A ^b   Ried, B ^b   Saunders, E A C M ^b   Somerville, E ^b   Spechio, L ^b   Neve, L A ^b   Tramacere, L ^b   Stefan, H ^b   Tartara, A ^b   Van As, A D ^b   Van Donsellar, C A ^b   Weber, M ^b   Wieser, H G ^b   Zaccara, G ^b   Gomez, G T ^b   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; VIGABATRIN;

ADOLESCENT; ADULT; AGED; AGITATION; AMNESIA; ANTICONVULSANT THERAPY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; VERTIGO; WEIGHT GAIN;

EID: 0033519964     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10531-7     Document Type: Article

References (37)

1. Jung M.J., Lippert B., Metcalf B.W.et al. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 29:1977;797-802.
2. Grove J., Schechter P.J., Tell G.et al. Increased gamma-butyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid). Life Sci. 28:1981;2431-2439.
3. Petroff O.A., Rothman D.L., Behar K.L., Mattson R.H. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology. 46:1996;1459-1463.
4. Gale K. Role of the substantia nigra in GABA-mediated anticonvulsant actions. Adv Neurol. 44:1986;343-364.
5. Schechter P.J., Trainer Y., Grove J. Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects. Mandel P., DeFeudes F.V. GABA: biochemistry and CNS functions. 1979;43-57 Plenum Press, New York.
6. Rimmer E.M., Richens A. Double-blind study of γ-vinyl GABA in patients with refractory epilepsy. Lancet. i:1984;189-190.
7. Gram L., Klosterkov P., Dam M. Gamma-vinyl GABA: a double-blind, placebo-controlled trial in partial epilepsy. Ann Neurol. 17:1985;262-266.
8. Loiseau P., Hardenberg J.P., Pestre M.et al. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia. 27:1986;115-120.
9. Tassinari C., Michelucci R., Ambrosetto G., Salvi F. Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Arch Neurol. 44:1987;907-910.
10. Marson A.G., Kadir Z.A., Chadwick D.W. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 313:1996;1169-1174.
11. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol. 27( suppl 1):1989;S43-S45.
12. Weiss K.L., Schroeder C.E., Kastin S.J.et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 44:1994;1944-1949.
13. Jackson G.D., Grunewald R.A., Connelly A., Duncan J.S. Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res. 18:1994;127-137.
14. Hammond E.J., Wilder B.J., Hurd R.W. Eight year experience with vigabatrin: clinical, neurophysiological, neuropathological studies. Epilepsia. 32 suppl( 1):1991;11. abstr.
15. Cannon D.J., Butler W.H., Mumford J.P., Lewis P.J. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol. 6( suppl 2):1991;S17-S24.
16. Eke T., Talbot J.F., Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. BMJ. 314:1997;180-181.
17. Marson A.G., Kadir Z.A., Hutton J.L., Chadwick D.W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 38:1997;859-880.
18. Sander J.W.A.S., Hart Y.M., Trimble M.R.et al. Vigabratin and psychosis. J Neurol Neurosurg Psychiatry. 53:1991;1008-1010.
19. Tanganelli P., Regesta G. Vigabatrin versus carbamazepine in newly diagnosed epileptic patients: a randomised response conditional crossover study. Epilepsia. 35( suppl 7):1994;S64. abstr.
20. Kälviäinen R., Äikiä M., Mervaala E.et al. Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy. Arch Neurol. 52:1995;989-996.
21. Jones B., Jarvis P., Lewis J.A.et al. Trials to assess equivalence: the importance of rigorous methods. BMJ. 313:1996;36-39.
22. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia. 39:1998;799-803.
23. Mattson R.H., Cramer J.A., Collins J.F.et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 313:1985;145-151.
24. Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic clonic seizures in adults. N Engl J Med. 327:1992;765-771.
25. Heller A.J., Chesterman P., Crawford P., Chadwick D., Johnson A.L., Reynolds E.H. Phenobarbitone, phenytoin, or sodium valproate for newly diagnosed epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry. 58:1995;44-50.
26. Verity C.M., Hosking G., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol. 37:1995;97-108.
27. Richens A., Davidson D.L., Cartlidge N.E., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry. 57:1994;682-687.
28. Krauss G.L., Johnson M.A., Miller N.R. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 50:1998;614-618.
29. Kälviäinen R., Nousiäinen I., Mantyjarvi M. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy controls. Epilepsia. 39( suppl 6):1998;72. abstr.
30. Chiron C., Dumas C., Jambaque I., Mumford J., Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberose sclerosis. Epilepsy Res. 26:1997;39-95.
31. Appleton R.E., Thornton L. Double blind comparison of vigabatrin versus placebo in newly diagnosed and previously untreated infantile spasms. Epilepsia. 37( suppl):1996;125. abstr.
32. Vigevano F., Cilio M.R. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 38:1997;1270-1274.
33. Brodie M.J., Richens A., Yuen A.W.C. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 345:1995;476-479.
34. Reunen M., Dam M., Yuen A.W.C. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. 23:1996;149-155.
35. Jacoby A., Buck D., Baker G., McNamee T., Graham-Jones S., Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia. 39:1998;776-786.
36. White H.S. Mechanisms of antiepileptic drugs. Porter R.J.C.D. The Epilepsies 2. 1997;1-30 Butterworth-Heinemann, New York.
37. Ferrendelli J.A. Rational polypharmacy. Epilepsia. 36:1995;115-118.